Trisodium 4-amino-5-hydroxy-3-[[4-[[2-oxo-1-[(phenylamino)carbonyl]propyl]azo]phenyl]azo]-6-[(4-sulphonato-1-naphthyl)azo]naphthalene-2,7-disulphonate

Endpoint summary

Description of key information

LD50 (oral, rat) > 5000 mg/kg b.w

LD50 (dermal, rat) > 5000 mg/kg b.w

Key value for chemical safety assessment

Acute toxicity: via oral route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Acute toxicity: via inhalation route

Endpoint conclusion

Endpoint conclusion:

no study available

Acute toxicity: via dermal route

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Justification for classification or non-classification

According to the CLP Regulation (EC 1272/2008), substances can be allocated to one of four toxicity categories based on acute toxicity by the oral, dermal or inhalation route according to the numeric criteria. Acute toxicity values are expressed as (approximate) LD50 (oral, dermal) or LC50 (inhalation) values or as acute toxicity estimates (ATE).

In the case of oral exposure route, the acute toxicity hazard categories and acute toxicity estimates (ATE) defining the respective categories are:

-Category 1: ATE ≤ 5 mg/kg bw

-Category 2: 5 < ATE ≤ 50 mg/kg bw

-Category 3: 50 < ATE ≤ 300 mg/kg bw

-Category 4: 300 < ATE ≤ 2000 mg/kg bw

In the case of dermal exposure route, the acute toxicity hazard categories and acute toxicity estimates (ATE) defining the respective categories are:

-Category 1: ATE ≤ 50 mg/kg bw

-Category 2: 50 < ATE ≤ 200 mg/kg bw

-Category 3: 200 < ATE ≤ 1000 mg/kg bw

-Category 4: 1000 < ATE ≤ 2000 mg/kg bw

The acute oral and dermal LD50 in rats were found to exceed 5000 mg/kg bw in both cases.

Therefore, the substance is not classified for oral and dermal acute toxicity according to the CLP Regulation (EC n. 1272/2008).